Stille AB (STIL.ST)
SEK 184.5
(-1.07%)
SEK 184.5
(-1.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 172.64 Million SEK | 13.03% |
| 2022 | 152.73 Million SEK | -4.99% |
| 2021 | 160.75 Million SEK | 198.5% |
| 2020 | 53.85 Million SEK | -9.39% |
| 2019 | 59.43 Million SEK | 103.51% |
| 2018 | 29.2 Million SEK | 38.17% |
| 2017 | 21.13 Million SEK | 16.8% |
| 2016 | 18.09 Million SEK | -11.82% |
| 2015 | 20.52 Million SEK | 19.03% |
| 2014 | 17.24 Million SEK | -17.85% |
| 2013 | 20.98 Million SEK | -27.7% |
| 2012 | 29.02 Million SEK | 18.18% |
| 2011 | 24.56 Million SEK | 50.8% |
| 2010 | 16.28 Million SEK | -31.05% |
| 2009 | 23.62 Million SEK | -6.24% |
| 2008 | 25.19 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 353.69 Million SEK | -1.14% |
| 2024 Q2 | 357.78 Million SEK | 0.65% |
| 2024 Q1 | 355.48 Million SEK | 105.91% |
| 2023 Q3 | 161.77 Million SEK | -0.49% |
| 2023 Q1 | 155.59 Million SEK | 1.87% |
| 2023 Q4 | 172.64 Million SEK | 6.72% |
| 2023 Q2 | 162.56 Million SEK | 4.48% |
| 2023 FY | 172.64 Million SEK | 13.03% |
| 2022 Q2 | 159.56 Million SEK | 1.8% |
| 2022 Q3 | 156.56 Million SEK | -1.88% |
| 2022 Q4 | 152.73 Million SEK | -2.45% |
| 2022 Q1 | 156.74 Million SEK | -2.49% |
| 2022 FY | 152.73 Million SEK | -4.99% |
| 2021 FY | 160.75 Million SEK | 198.5% |
| 2021 Q1 | 58.48 Million SEK | 8.59% |
| 2021 Q2 | 58.88 Million SEK | 0.7% |
| 2021 Q3 | 176.44 Million SEK | 199.62% |
| 2021 Q4 | 160.75 Million SEK | -8.89% |
| 2020 FY | 53.85 Million SEK | -9.39% |
| 2020 Q4 | 53.85 Million SEK | 7.83% |
| 2020 Q3 | 49.94 Million SEK | -2.26% |
| 2020 Q2 | 51.09 Million SEK | -8.81% |
| 2020 Q1 | 56.02 Million SEK | -5.73% |
| 2019 Q1 | 31.11 Million SEK | 6.55% |
| 2019 Q3 | 30.46 Million SEK | -5.65% |
| 2019 Q4 | 59.43 Million SEK | 95.07% |
| 2019 Q2 | 32.29 Million SEK | 3.78% |
| 2019 FY | 59.43 Million SEK | 103.51% |
| 2018 Q2 | 22.47 Million SEK | -0.34% |
| 2018 FY | 29.2 Million SEK | 38.17% |
| 2018 Q4 | 29.2 Million SEK | 30.25% |
| 2018 Q3 | 22.42 Million SEK | -0.22% |
| 2018 Q1 | 22.54 Million SEK | 6.67% |
| 2017 Q3 | 21.87 Million SEK | 3.1% |
| 2017 Q2 | 21.21 Million SEK | 6.49% |
| 2017 Q1 | 19.92 Million SEK | 10.08% |
| 2017 FY | 21.13 Million SEK | 16.8% |
| 2017 Q4 | 21.13 Million SEK | -3.36% |
| 2016 Q2 | 18.23 Million SEK | -4.86% |
| 2016 Q1 | 19.16 Million SEK | -6.6% |
| 2016 FY | 18.09 Million SEK | -11.82% |
| 2016 Q4 | 18.09 Million SEK | 3.68% |
| 2016 Q3 | 17.45 Million SEK | -4.29% |
| 2015 Q2 | 17.3 Million SEK | -1.73% |
| 2015 Q1 | 17.61 Million SEK | 2.14% |
| 2015 FY | 20.52 Million SEK | 19.03% |
| 2015 Q4 | 20.52 Million SEK | 10.62% |
| 2015 Q3 | 18.55 Million SEK | 7.2% |
| 2014 Q3 | 18.34 Million SEK | 14.09% |
| 2014 Q2 | 16.08 Million SEK | -14.57% |
| 2014 Q1 | 18.82 Million SEK | -10.31% |
| 2014 FY | 17.24 Million SEK | -17.85% |
| 2014 Q4 | 17.24 Million SEK | -6.02% |
| 2013 Q2 | 30.43 Million SEK | 17.97% |
| 2013 Q1 | 25.79 Million SEK | -11.14% |
| 2013 FY | 20.98 Million SEK | -27.7% |
| 2013 Q3 | 21.57 Million SEK | -29.1% |
| 2013 Q4 | 20.98 Million SEK | -2.73% |
| 2012 Q2 | 28.25 Million SEK | -1.65% |
| 2012 Q1 | 28.73 Million SEK | 16.97% |
| 2012 Q3 | 29.98 Million SEK | 6.12% |
| 2012 Q4 | 29.02 Million SEK | -3.19% |
| 2012 FY | 29.02 Million SEK | 18.18% |
| 2011 Q2 | 19.97 Million SEK | 13.68% |
| 2011 Q1 | 17.57 Million SEK | 7.9% |
| 2011 FY | 24.56 Million SEK | 50.8% |
| 2011 Q3 | 20.66 Million SEK | 3.41% |
| 2011 Q4 | 24.56 Million SEK | 18.89% |
| 2010 Q1 | 18.04 Million SEK | -23.63% |
| 2010 FY | 16.28 Million SEK | -31.05% |
| 2010 Q4 | 16.28 Million SEK | -2.09% |
| 2010 Q3 | 16.63 Million SEK | -11.44% |
| 2010 Q2 | 18.78 Million SEK | 4.13% |
| 2009 FY | 23.62 Million SEK | -6.24% |
| 2009 Q4 | 23.62 Million SEK | 0.0% |
| 2009 Q2 | 21.42 Million SEK | -26.38% |
| 2009 Q1 | 29.1 Million SEK | 0.0% |
| 2008 FY | 25.19 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -1469.74% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 93.544% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 93.544% |
| Arcoma AB | 33.3 Million SEK | -418.361% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 47.637% |
| BICO Group AB (publ) | 3.26 Billion SEK | 94.712% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 38.321% |
| CellaVision AB (publ) | 212.32 Million SEK | 18.69% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -1116.032% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -2413.343% |
| C-Rad AB (publ) | 122.4 Million SEK | -41.046% |
| Duearity AB (publ) | 17.53 Million SEK | -884.826% |
| Dignitana AB (publ) | 37.56 Million SEK | -359.552% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -771.919% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.301% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -738.046% |
| Iconovo AB (publ) | 14.55 Million SEK | -1086.212% |
| Integrum AB (publ) | 22.07 Million SEK | -682.137% |
| Luxbright AB (publ) | 7 Million SEK | -2366.243% |
| Mentice AB (publ) | 163.55 Million SEK | -5.555% |
| OssDsign AB (publ) | 105.25 Million SEK | -64.018% |
| Paxman AB (publ) | 44.5 Million SEK | -287.877% |
| Promimic AB (publ) | 16.15 Million SEK | -968.581% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -177.695% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -711.354% |
| ScandiDos AB (publ) | 37.18 Million SEK | -364.261% |
| Sectra AB (publ) | 1.64 Billion SEK | 89.482% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -291.812% |
| Senzime AB (publ) | 58.06 Million SEK | -197.322% |
| SpectraCure AB (publ) | 14.97 Million SEK | -1052.855% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 95.293% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 31.1% |